307 related articles for article (PubMed ID: 19240962)
1. Rechallenge with temozolomide in patients with recurrent gliomas.
Wick A; Pascher C; Wick W; Jauch T; Weller M; Bogdahn U; Hau P
J Neurol; 2009 May; 256(5):734-41. PubMed ID: 19240962
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
[TBL] [Abstract][Full Text] [Related]
4. Rechallenge temozolomide in glioma: A case series from India.
Patil VM; Tonse R; Kothari R; Chandrasekaran A; Pande N; Epari S; Gupta T; Jalali R
Indian J Cancer; 2017; 54(1):368-371. PubMed ID: 29199725
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
6. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
[TBL] [Abstract][Full Text] [Related]
8. [Temozolomide in the treatment of recurrent malignant glioma].
Kobayashi H; Sawamura Y; Ishii N; Murata J; Iwasaki Y
No Shinkei Geka; 2006 Dec; 34(12):1241-7. PubMed ID: 17154070
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
[TBL] [Abstract][Full Text] [Related]
10. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Chamberlain MC
Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Kong DS; Lee JI; Kim JH; Kim ST; Kim WS; Suh YL; Dong SM; Nam DH
Neuro Oncol; 2010 Mar; 12(3):289-96. PubMed ID: 20167817
[TBL] [Abstract][Full Text] [Related]
13. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Khasraw M; Bell D; Wheeler H
J Clin Neurosci; 2009 Jun; 16(6):854-5. PubMed ID: 19303779
[TBL] [Abstract][Full Text] [Related]
14. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
[TBL] [Abstract][Full Text] [Related]
15. Rechallenge with temozolomide in recurrent glioma.
Gaviani P; Silvani A; Lamperti E; Botturi A; Fariselli L; Simonetti G; Ferrari D; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S247-9. PubMed ID: 21987286
[TBL] [Abstract][Full Text] [Related]
16. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
17. Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Yang P; Zhang C; Cai J; You G; Wang Y; Qiu X; Li S; Wu C; Yao K; Li W; Peng X; Zhang W; Jiang T
Oncotarget; 2016 Nov; 7(48):80091-80100. PubMed ID: 27590514
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Brada M; Stenning S; Gabe R; Thompson LC; Levy D; Rampling R; Erridge S; Saran F; Gattamaneni R; Hopkins K; Beall S; Collins VP; Lee SM
J Clin Oncol; 2010 Oct; 28(30):4601-8. PubMed ID: 20855843
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Kong DS; Lee JI; Kim WS; Son MJ; Lim DH; Kim ST; Park K; Kim JH; Eoh W; Nam DH
Oncol Rep; 2006 Nov; 16(5):1117-21. PubMed ID: 17016602
[TBL] [Abstract][Full Text] [Related]
20. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
